SM
MDGL icon

Sabby Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Sabby Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-85
Closed -$1.89M – 236
2013
Q3 		$1.89M Buy
85
+23
+37% +$4.89K 0.12% 88
2013
Q2 		$1.09M Buy
+62
New +$16.2K 0.07% 113

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sabby Management's MDGL Position: Q4 2018 in Review

Sabby Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2018, closing a stake of 1,500 shares — an estimated $232K sold.

Sabby Management first reported a position in MDGL in Q2 2013 and held it in 4 quarters. The position peaked at $1.58M in Q3 2013. 136 funds tracked by Wall St. Rank hold MDGL as of Q4 2018.

  • Sabby Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Sabby Management sold 1,500 Madrigal Pharmaceuticals shares in Q4 2018, an estimated $232K.
  • Sabby Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Sabby Management's Madrigal Pharmaceuticals position peaked at $1.58M in Q3 2013.
  • 136 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2018.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.